Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PARKERVISION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PARKERVISION's regulatory disclosures and financial reporting.
ParkerVision Inc. director Anthony B. Bowers has filed an initial Form 3 showing his equity stake in the company. He holds 165,000 shares of Common Stock directly. He also holds a Nonqualified Stock Option covering 300,000 shares of Common Stock at an exercise price of $0.20 per share, expiring on May 19, 2031. According to the footnote, this option was granted on May 19, 2026 for his first year of Board and committee service and vests in two equal installments on November 19, 2026 and May 19, 2027.
ParkerVision, Inc. files a Prospectus Supplement registering 9,387,500 shares of Common Stock for resale by the selling shareholders. The registered shares consist of 2,843,750 issued shares, 6,343,750 shares issuable upon conversion of Convertible Notes at a fixed conversion price of $0.16 per share, and 200,000 shares issuable upon exercise of Options. The company will not receive proceeds from resale by the selling shareholders; if the Options are exercised for cash, the company could receive up to $42,620 in gross proceeds. This supplement updates the Prospectus with information furnished on May 21, 2026.
ParkerVision, Inc. registers 16,638,353 shares of Common Stock for resale by selling shareholders.
The shares are issuable upon conversion of convertible promissory notes dated between May 10, 2022 and August 3, 2022 at a fixed conversion price of $0.13 per share. This Prospectus Supplement (dated May 21, 2026) supplements the Prospectus dated August 22, 2022 and attaches a Form 8-K furnished on May 21, 2026. The resale registration covers shares held by the selling shareholders named in the Prospectus.
ParkerVision, Inc. files a Prospectus Supplement registering 1,578,946 shares of Common Stock for resale by a selling stockholder.
The registration covers an aggregate of 1,052,631 shares and 526,315 shares underlying warrants issued under a December 14, 2021 agreement. The company will not receive proceeds from resales; if the Warrants are exercised for cash, ParkerVision would receive up to $526,315, which it expects to use for general working capital, including payment of litigation expenses. The supplement attaches a Form 8-K disclosing that director Lewis Titterton resigned effective May 15, 2026 and that Anthony Bowers was appointed to the Board and its Audit and Compensation Committees on May 19, 2026.
ParkerVision, Inc. is updating a resale prospectus to register 13,342,953 shares of Common Stock for resale by selling stockholders under the Prospectus Supplement dated May 21, 2026. The shares consist of several issuances, including 7,962,722 shares issued under earlier purchase agreements, 3,230,942 shares plus 1,619,289 shares underlying warrants, and 530,000 shares issued for services.
The company states it will not receive proceeds from resale of the registered shares; however, if the Warrants are exercised for cash, the company would receive up to $2,833,756, which it expects to use for general working capital, including payment of litigation expenses. The supplement attaches a Form 8-K that discloses a director resignation on May 15, 2026 and the appointment of a new director on May 19, 2026. The company’s common stock trades on the OTCQB under the symbol PRKR.
ParkerVision, Inc. registers 5,871,584 shares of Common Stock for resale by selling stockholders under a Prospectus Supplement dated May 21, 2026. The company will not receive proceeds from these resales. The supplement attaches a Form 8-K filed May 21, 2026, which furnishes a press release.
The Form 8-K discloses a director resignation and board appointment: May 15, 2026 resignation of Lewis Titterton (retirement) and appointment of Anthony Bowers on May 19, 2026, who joins the Audit and Compensation Committees and will receive standard non-employee director compensation and the company’s standard indemnification agreement.
ParkerVision, Inc. files a prospectus supplement registering 16,809,295 shares of Common Stock for resale by selling stockholders under its April 28, 2020 prospectus. The supplement notes the company will not receive proceeds from those resales; cash proceeds up to $3,900,000 may result if certain warrants are exercised.
The filing also furnishes a Form 8-K reporting the resignation of director Lewis Titterton due to retirement and the Board's appointment of Anthony Bowers to fill the vacancy and to serve on the Audit and Compensation Committees.
ParkerVision, Inc. files a prospectus supplement registering 18,014,164 shares of Common Stock for resale by selling stockholders.
The shares comprise convertible-note conversions, consulting issuances and a warrant; the company will not receive proceeds from resales, except it would receive up to $180,000 if the Park Consulting Warrant is exercised for cash. The supplement incorporates an attached Form 8-K describing a director resignation and appointment.
ParkerVision, Inc. filed a prospectus supplement registering 17,189,660 shares of Common Stock for resale by selling stockholders pursuant to prior registration statements.
The supplement confirms the company will not receive proceeds from resales, although it may receive proceeds from certain warrant exercises (up to $700,000 and up to $1,763,500 related to Aspire Capital arrangements). The supplement also furnishes a Form 8-K reporting a director resignation and appointment.
ParkerVision, Inc. files a Prospectus Supplement registering 12,800,000 shares of Common Stock for resale by selling stockholders, consisting of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from resales by selling stockholders; if the warrant is exercised for cash, the company would receive up to $800,000 in gross proceeds to fund patent enforcement actions and for working capital. This supplement incorporates an attached Form 8-K that discloses a director resignation and a new director appointment.